Bolt Biotherapeutics (BOLT) Competitors $5.44 -0.18 (-3.20%) Closing price 04:00 PM EasternExtended Trading$5.64 +0.20 (+3.77%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. SABS, CRIS, AMGN, GILD, VRTX, REGN, ALNY, BIIB, INCY, and UTHRShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include SAB Biotherapeutics (SABS), Curis (CRIS), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Its Competitors SAB Biotherapeutics Curis Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Incyte United Therapeutics Bolt Biotherapeutics (NASDAQ:BOLT) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Which has stronger valuation and earnings, BOLT or SABS? SAB Biotherapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$7.69M1.36-$63.12M-$33.40-0.16SAB BiotherapeuticsN/AN/A-$34.10M-$4.00-0.55 Does the media favor BOLT or SABS? In the previous week, SAB Biotherapeutics had 1 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 4 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.93 beat SAB Biotherapeutics' score of -0.47 indicating that Bolt Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate BOLT or SABS? Bolt Biotherapeutics presently has a consensus price target of $50.00, suggesting a potential upside of 819.12%. SAB Biotherapeutics has a consensus price target of $11.00, suggesting a potential upside of 397.74%. Given Bolt Biotherapeutics' higher probable upside, equities analysts plainly believe Bolt Biotherapeutics is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BOLT or SABS more profitable? Bolt Biotherapeutics' return on equity of -94.51% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt BiotherapeuticsN/A -94.51% -59.07% SAB Biotherapeutics N/A -153.92%-89.16% Do institutionals and insiders have more ownership in BOLT or SABS? 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 6.1% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 27.8% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, BOLT or SABS? Bolt Biotherapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. SummaryBolt Biotherapeutics beats SAB Biotherapeutics on 8 of the 14 factors compared between the two stocks. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.45M$3.08B$5.60B$9.82BDividend YieldN/A2.27%4.60%4.11%P/E Ratio-0.1620.5630.2825.72Price / Sales1.36191.64387.9280.32Price / CashN/A42.0537.7558.93Price / Book0.187.598.456.01Net Income-$63.12M-$54.65M$3.25B$265.06M7 Day Performance-3.55%5.43%4.05%2.80%1 Month Performance-8.72%6.75%4.32%1.68%1 Year Performance-60.58%31.59%36.25%29.59% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics3.1614 of 5 stars$5.44-3.2%$50.00+819.1%-59.9%$10.45M$7.69M-0.1690News CoverageEarnings ReportSABSSAB Biotherapeutics2.3318 of 5 stars$2.28+2.2%$13.00+470.2%-8.5%$20.71M$1.32M-0.62140Earnings ReportShort Interest ↑Analyst RevisionCRISCuris3.2014 of 5 stars$1.60-1.8%$17.00+962.5%-61.2%$17.05M$11.20M-0.2660Analyst RevisionAMGNAmgen4.667 of 5 stars$301.94+1.7%$307.27+1.8%-10.5%$159.63B$33.42B27.5528,000Trending NewsAnalyst RevisionGILDGilead Sciences4.8573 of 5 stars$114.51+1.2%$112.36-1.9%+62.4%$140.79B$28.75B24.1117,600Positive NewsEarnings ReportDividend AnnouncementAnalyst RevisionVRTXVertex Pharmaceuticals4.9439 of 5 stars$472.27+2.2%$509.89+8.0%-15.3%$118.67B$11.02B-120.486,100Positive NewsHigh Trading VolumeREGNRegeneron Pharmaceuticals4.8388 of 5 stars$571.54+2.3%$832.73+45.7%-51.5%$60.34B$14.21B14.4015,106Positive NewsDividend AnnouncementAnalyst ForecastALNYAlnylam Pharmaceuticals4.2593 of 5 stars$419.55+4.4%$396.04-5.6%+61.6%$52.67B$2.25B-169.862,230Positive NewsAnalyst RevisionBIIBBiogen4.9148 of 5 stars$132.20+0.2%$185.63+40.4%-33.7%$19.35B$9.68B12.647,605Analyst ForecastAnalyst RevisionINCYIncyte4.5886 of 5 stars$78.04+3.2%$79.73+2.2%+38.4%$14.76B$4.24B17.742,617UTHRUnited Therapeutics4.9347 of 5 stars$292.65-0.6%$379.69+29.7%-4.3%$13.27B$2.88B11.421,305Positive NewsAnalyst Forecast Related Companies and Tools Related Companies SAB Biotherapeutics Alternatives Curis Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access